Cargando…
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
OBJECTIVE: We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell subpopulations (CD14+, CD4+ and CD8+) from patients with multiple sclerosis...
Autores principales: | López-Gómez, Carlos, Oliver-Martos, Begoña, Pinto-Medel, María-Jesús, Suardiaz, Margarita, Reyes-Garrido, Virginia, Urbaneja, Patricia, Fernández, Óscar, Leyva, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752633/ https://www.ncbi.nlm.nih.gov/pubmed/25736057 http://dx.doi.org/10.1136/jnnp-2014-309932 |
Ejemplares similares
-
TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011) -
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021) -
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019) -
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022) -
Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
por: López-Gómez, Carlos, et al.
Publicado: (2013)